NASDAQ:PRVA

Privia Health Group (PRVA) Stock Price, News & Analysis

$18.17
+0.14 (+0.78%)
(As of 10:57 AM ET)
Today's Range
$17.94
$18.59
50-Day Range
$17.69
$22.92
52-Week Range
$17.54
$30.15
Volume
77,542 shs
Average Volume
931,813 shs
Market Capitalization
$2.16 billion
P/E Ratio
95.64
Dividend Yield
N/A
Price Target
$27.62

Privia Health Group MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
52.2% Upside
$27.62 Price Target
Short Interest
Healthy
6.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.42mentions of Privia Health Group in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$69,889 Sold Last Quarter
Proj. Earnings Growth
30.77%
From $0.26 to $0.34 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.42 out of 5 stars

Medical Sector

116th out of 924 stocks

Health Services Industry

2nd out of 11 stocks

PRVA stock logo

About Privia Health Group Stock (NASDAQ:PRVA)

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia.

PRVA Stock Price History

PRVA Stock News Headlines

Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
Where Privia Health Gr Stands With Analysts
PRVA: Rating increased to a HOLD
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
Analyst Scoreboard: 8 Ratings For Privia Health Gr
Forecasting The Future: 4 Analyst Projections For Privia Health Gr
RBC Capital Keeps Their Buy Rating on Privia Health Group (PRVA)
Privia Health Gr's Earnings: A Preview
Privia Health Group Inc (PRVA)
See More Headlines
Receive PRVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Privia Health Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
5/02/2024
Next Earnings (Confirmed)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVA
Fax
N/A
Employees
1,102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.62
High Stock Price Target
$40.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+53.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$23.08 million
Pretax Margin
1.75%

Debt

Sales & Book Value

Annual Sales
$1.66 billion
Cash Flow
$0.25 per share
Book Value
$5.14 per share

Miscellaneous

Free Float
101,807,000
Market Cap
$2.14 billion
Optionable
Optionable
Beta
0.81
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

PRVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Privia Health Group stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Privia Health Group in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PRVA shares.
View PRVA analyst ratings
or view top-rated stocks.

What is Privia Health Group's stock price target for 2024?

12 Wall Street research analysts have issued 1-year price targets for Privia Health Group's stock. Their PRVA share price targets range from $21.00 to $40.00. On average, they predict the company's stock price to reach $27.62 in the next twelve months. This suggests a possible upside of 52.2% from the stock's current price.
View analysts price targets for PRVA
or view top-rated stocks among Wall Street analysts.

How have PRVA shares performed in 2024?

Privia Health Group's stock was trading at $23.03 at the beginning of 2024. Since then, PRVA shares have decreased by 21.2% and is now trading at $18.14.
View the best growth stocks for 2024 here
.

When is Privia Health Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PRVA earnings forecast
.

How can I listen to Privia Health Group's earnings call?

Privia Health Group will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Privia Health Group's earnings last quarter?

Privia Health Group, Inc. (NASDAQ:PRVA) announced its earnings results on Tuesday, February, 27th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.02. The firm earned $440.80 million during the quarter, compared to analyst estimates of $425.81 million. Privia Health Group had a trailing twelve-month return on equity of 3.97% and a net margin of 1.39%. The firm's revenue for the quarter was up 21.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.14 EPS.

What guidance has Privia Health Group issued on next quarter's earnings?

Privia Health Group issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.6 billion-$1.7 billion, compared to the consensus revenue estimate of $1.9 billion.

When did Privia Health Group IPO?

Privia Health Group (PRVA) raised $351 million in an IPO on Thursday, April 29th 2021. The company issued 19,500,000 shares at $17.00-$19.00 per share. Goldman Sachs, J.P. Morgan, Credit Suisse, Piper Sandler and William Blair acted as the underwriters for the IPO and Canaccord Genuity, Truist Securities, R. Seelaus & Co. and Siebert Williams Shank were co-managers.

Who are Privia Health Group's major shareholders?

Privia Health Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (4.55%), Principal Financial Group Inc. (2.89%), WCM Investment Management LLC (0.48%), Peregrine Capital Management LLC (0.24%), State of Alaska Department of Revenue (0.05%) and Janney Montgomery Scott LLC (0.05%). Insiders that own company stock include Advisors LLC Mbd, David Mountcastle, Jeffrey B Butler, Jeffrey Daniel Bernstein, Matthew Shawn Morris, Pamplona Capital Partners Iii,, Parth Mehrotra, Thomas Bartrum and William M Sullivan.
View institutional ownership trends
.

How do I buy shares of Privia Health Group?

Shares of PRVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRVA) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners